The Institute for Clinical and Economic Review (ICER) on Thursday, Feb. 20, released a draft evidence report on treatments for cystic fibrosis.
The report assesses the effectiveness and value of Vertex’s Trikafta, as well as considers new data on three other drugs from Vertex: Symdeko, Orkambi and Kalydeco.
According to a press release, ICER is accepting public input on the draft report until 5 p.m. EST March 18.
To read the report, click here.
Click here to read the full press release.